Company intelligence / Profile preview

CatalYm

Munich/Martinsried, Bavaria, Germanycatalym.com ↗

Ownership: Private
Development stage: Phase 2

Overview

CatalYm’s lead antibody, visugromab, has shown durable anti-tumor efficacy and long-lasting objective responses in relapsed and refractory metastatic solid tumor patients when combined with anti-PD‑1 therapy. In the GDFATHER trial, an objective response rate of ~16.7% was observed across heavily pretreated patients with NSCLC, urothelial carcinoma, and HCC. The average duration of response exceeded 15 months for NSCLC; most responses are ongoing. Safety profile has been excellent to date.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodies (mAbs)
Industry: Biotech

Drug pipeline

3 assets

visugromab

2 more assets in the full pipeline.

Request access →

Partnerships

Clinical collaboration with Bristol Myers Squibb for combination trials using Opdivo/nivolumab as anti-PD–1 backbone therapy

Beyond the preview

Go deeper on CatalYm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CatalYm.

Explore the full profile